All lobbying filings

RARE DISEASE COMPANY COALITION

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $110,000.00 expenses · posted Apr 20, 2026

Official filing document

Bills named in this filing 2

HR 1262
Mikaela Naylon Give Kids a Chance Act
HR 1762
Forest Service Accountability Act

Lobbying activity 2

Pharmacy

HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals

Trade (domestic/foreign)

Proclamation 11020 - Section 232 Pharmaceutical Tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.